Literature DB >> 19126778

Dominant cataract formation in association with a vimentin assembly disrupting mutation.

Martin Müller1, Shomi S Bhattacharya, Tony Moore, Quincy Prescott, Tatjana Wedig, Harald Herrmann, Thomas M Magin.   

Abstract

Cataracts are characterized by an opacification of the eye lens, often caused by protein misfolding and aggregation. The intermediate filament protein vimentin, which is highly expressed in lens fiber cells and in mesenchymal tissues, is a main structural determinant in these cells forming a membrane-connected cytoskeleton. Additional functions of vimentin remain to be identified. Here, we demonstrate that a mutation in VIM causes a dominant, pulverulent cataract. We sequenced the complete human VIM gene in 90 individuals suffering from congenital cataract and found a G596A change in exon 1 in a single individual, causing the missense mutation E151K in coil 1B of vimentin. The mutant vimentin formed an aberrant vimentin cytoskeleton and increased the proteasome activity in transfected cells. Furthermore, this mutation causes a severe kinetic defect in vimentin assembly both in vitro and in vivo. Hence, in conjunction with available mouse and cell culture models, our results reveal for the first time an important functional role for vimentin in the maintenance of lens integrity. Finally, this invites novel therapy approaches for cataracts.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19126778     DOI: 10.1093/hmg/ddn440

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  45 in total

Review 1.  Molecular Genetics of Cataract.

Authors:  Alan Shiels; J Fielding Hejtmancik
Journal:  Prog Mol Biol Transl Sci       Date:  2015-06-12       Impact factor: 3.622

Review 2.  Inherited Congenital Cataract: A Guide to Suspect the Genetic Etiology in the Cataract Genesis.

Authors:  Olga Messina-Baas; Sergio A Cuevas-Covarrubias
Journal:  Mol Syndromol       Date:  2017-02-07

Review 3.  Intermediate filaments: primary determinants of cell architecture and plasticity.

Authors:  Harald Herrmann; Sergei V Strelkov; Peter Burkhard; Ueli Aebi
Journal:  J Clin Invest       Date:  2009-07-01       Impact factor: 14.808

Review 4.  "IF-pathies": a broad spectrum of intermediate filament-associated diseases.

Authors:  M Bishr Omary
Journal:  J Clin Invest       Date:  2009-07-01       Impact factor: 14.808

Review 5.  Functions of the intermediate filament cytoskeleton in the eye lens.

Authors:  Shuhua Song; Andrew Landsbury; Ralf Dahm; Yizhi Liu; Qingjiong Zhang; Roy A Quinlan
Journal:  J Clin Invest       Date:  2009-07-01       Impact factor: 14.808

Review 6.  Introducing intermediate filaments: from discovery to disease.

Authors:  John E Eriksson; Thomas Dechat; Boris Grin; Brian Helfand; Melissa Mendez; Hanna-Mari Pallari; Robert D Goldman
Journal:  J Clin Invest       Date:  2009-07-01       Impact factor: 14.808

7.  Electron paramagnetic resonance analysis of the vimentin tail domain reveals points of order in a largely disordered region and conformational adaptation upon filament assembly.

Authors:  John F Hess; Madhu S Budamagunta; Atya Aziz; Paul G FitzGerald; John C Voss
Journal:  Protein Sci       Date:  2013-01       Impact factor: 6.725

Review 8.  Cat-Map: putting cataract on the map.

Authors:  Alan Shiels; Thomas M Bennett; J Fielding Hejtmancik
Journal:  Mol Vis       Date:  2010-10-08       Impact factor: 2.367

9.  Vimentin coordinates fibroblast proliferation and keratinocyte differentiation in wound healing via TGF-β-Slug signaling.

Authors:  Fang Cheng; Yue Shen; Ponnuswamy Mohanasundaram; Michelle Lindström; Johanna Ivaska; Tor Ny; John E Eriksson
Journal:  Proc Natl Acad Sci U S A       Date:  2016-07-08       Impact factor: 11.205

10.  Down regulation of the PEDF gene in human lens epithelium cells changed the expression of proteins vimentin and alphaB-crystallin.

Authors:  Jing Yang; Lixia Luo; Xialin Liu; Mark I Rosenblatt; Bo Qu; Yuhua Liu; Yizhi Liu
Journal:  Mol Vis       Date:  2010-01-26       Impact factor: 2.367

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.